Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months
Open Access
- 23 March 2015
- journal article
- research article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 187 (7), E215-E223
- https://doi.org/10.1503/cmaj.141200
Abstract
Background: The multicomponent serogroup B meningococcal (4CMenB) vaccine induces antibodies against indicator strains of serogroup B meningococcus under various schedules. We investigated the persistence of antibodies in 5-year-old children 18–20 months after their last dose (at about 3.5 years of age). Methods: We assessed 5-year-old children who received the 4CMenB vaccine or a recombinant protein vaccine in a previous randomized trial. We also recruited 50 vaccine-naive 5-year-olds and administered 2 doses of 4CMenB to each child. We measured serum bactericidal antibody titres against 4 indicator strains of serogroup B meningococcus matched to each individual vaccine component and against 4 mismatched strains. Results: Of those who received the 4CMenB vaccine at 2, 4, 6, 12 and 40 months (n = 16), the percentage with protective antibody titres (≥ 1:4) at 60 months ranged from 44% to 88% against matched strains and from 13% to 81% against mismatched strains. Loss of protective titres was also observed for those who received the 4CMenB vaccine at 12, 40 and 42 months (n = 5) (80%–100% against matched strains, 60%–100% against mismatched strains) or at 40 and 42 months (n = 29) (31%–100% against matched strains, 41%–81% against mismatched strains). Administering the 4CMenB vaccine to 5-year-old children yielded protective titres against matched strains in 92%–100% and against mismatched strains in 59%–100%. The majority of these children reported injection-site pain (40/50 [80%] after dose 1, 39/46 [85%] after dose 2) and erythema (47/50 [94%] and 40/46 [87%], respectively); rates of fever were low (5/50 [10%] and 2/46 [4%], respectively). Interpretation: Waning of immunity by 5 years of age occurred after receipt of the 4CMenB vaccine in infancy, even with an additional booster at 40 months. The 4CMenB vaccine is immunogenic and was fairly well tolerated by 5-year-old children, although injection-site pain was noteworthy. Trial registration:ClinicalTrials.gov, no. NCT01027351Keywords
This publication has 13 references indexed in Scilit:
- Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)Vaccine, 2013
- Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccineHuman Vaccines & Immunotherapeutics, 2013
- Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverageVaccine, 2013
- Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster doseCMAJ : Canadian Medical Association Journal, 2013
- A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?Expert Review of Vaccines, 2013
- Invasive meningococcal disease in England and Wales: Implications for the introduction of new vaccinesVaccine, 2012
- Multicenter, Open‐Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in InfancyClinical Infectious Diseases, 2010
- Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifeThe Pediatric Infectious Disease Journal, 2010
- A RANDOMIZED, DOUBLE-BLIND STUDY EXAMINING THE COMPARATIVE EFFICACIES AND SAFETY OF INHALED EPINEPHRINE AND NASAL DECONGESTANT IN HOSPITALIZED INFANTS WITH ACUTE BRONCHIOLITISThe Pediatric Infectious Disease Journal, 2010
- Neisseria meningitidis group B correlates of protection and assay standardization—International Meeting Report Emory University, Atlanta, Georgia, United States, 16–17 March 2005Vaccine, 2006